Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (fibroblasts) | 0.10 |
| chemistry Open Targets | compounds already reach it: marimastat, cts-1027 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 37 Parkinson's papers of 8,571 | 0.52 |
| pathways Reactome | 7 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 3031
Sealed predictions
- MMP3 in dopamine neurons, braak-0.41 (p 0.269) → +0.24 (p 0.530)receipt 3037
Swarm cases
receipt 3037: MMP3 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.781, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to +0.02, sign flips 1; without severely affected donors -0.09 (p 0.722, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MMP3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts